Challenges of Colistin Use in ICU and Therapeutic Drug
Monitoring: A Literature Review

J 2023

Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review

RYCHLÍČKOVÁ, Jitka, Vendula KUBICKOVA, Pavel SUK a Karel URBANEK

Základní údaje

Originální název

Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review

Autoři

RYCHLÍČKOVÁ, Jitka (203 Česká republika, domácí), Vendula KUBICKOVA (203 Česká republika), Pavel SUK (203 Česká republika, domácí) a Karel URBANEK (203 Česká republika, garant)

Vydání

Antibiotics-Basel, BASEL, MDPI, 2023, 2079-6382

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.800 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130973

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/antibiotics12030437

UT WoS

000983473900001

Klíčová slova anglicky

colistin; quantification methods; drug stability; pharmacokinetics; drug monitoring

Štítky

14110122, 14110516, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 6. 2023 15:12, Mgr. Tereza Miškechová

Anotace

V originále

The emerging resistance of Gram-negative bacteria is a growing problem worldwide. Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics or their combinations, it has led to the reintroduction of colistin as a therapeutic alternative. Despite its protracted development and availability on the market, there is now a complex maze of questions surrounding colistin with a more or less straightforward relationship to its safety and efficacy. This review aims to offer a way to navigate this maze. We focus on summarizing the available literature regarding the use of colistin in critically ill patients, particularly on stability, pharmacokinetics, methods for determining plasma concentrations, and therapeutic drug monitoring benefits and limitations. Based on these data, we then highlight the main gaps in the available information and help define directions for future research on this drug. The first gap is the lack of data on the stability of intravenous and nebulization solutions at clinically relevant concentrations and under external conditions corresponding to clinical practice. Furthermore, pharmacokinetic-pharmacodynamic parameters should be validated using standardized dosing, including a loading dose. Based on the pharmacokinetic data obtained, a population model for critically ill patients should be developed. Finally, the interference of colistin with extracorporeal methods should be quantified.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)

Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

Citovat

RYCHLÍČKOVÁ, Jitka, Vendula KUBICKOVA, Pavel SUK a Karel URBANEK. Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review. Antibiotics-Basel. BASEL: MDPI, 2023, roč. 12, č. 3, s. 1-17. ISSN 2079-6382. Dostupné z: https://dx.doi.org/10.3390/antibiotics12030437.

@article{2291648,
   author = {Rychlíčková, Jitka and Kubickova, Vendula and Suk, Pavel and Urbanek, Karel},
   article_location = {BASEL},
   article_number = {3},
   doi = {http://dx.doi.org/10.3390/antibiotics12030437},
   keywords = {colistin; quantification methods; drug stability; pharmacokinetics; drug monitoring},
   language = {eng},
   issn = {2079-6382},
   journal = {Antibiotics-Basel},
   title = {Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review},
   url = {https://www.mdpi.com/2079-6382/12/3/437},
   volume = {12},
   year = {2023}
}

TY  - JOUR
ID  - 2291648
AU  - Rychlíčková, Jitka - Kubickova, Vendula - Suk, Pavel - Urbanek, Karel
PY  - 2023
TI  - Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review
JF  - Antibiotics-Basel
VL  - 12
IS  - 3
SP  - 1-17
EP  - 1-17
PB  - MDPI
SN  - 20796382
KW  - colistin
KW  - quantification methods
KW  - drug stability
KW  - pharmacokinetics
KW  - drug monitoring
UR  - https://www.mdpi.com/2079-6382/12/3/437
N2  - The emerging resistance of Gram-negative bacteria is a growing problem worldwide. Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics or their combinations, it has led to the reintroduction of colistin as a therapeutic alternative. Despite its protracted development and availability on the market, there is now a complex maze of questions surrounding colistin with a more or less straightforward relationship to its safety and efficacy. This review aims to offer a way to navigate this maze. We focus on summarizing the available literature regarding the use of colistin in critically ill patients, particularly on stability, pharmacokinetics, methods for determining plasma concentrations, and therapeutic drug monitoring benefits and limitations. Based on these data, we then highlight the main gaps in the available information and help define directions for future research on this drug. The first gap is the lack of data on the stability of intravenous and nebulization solutions at clinically relevant concentrations and under external conditions corresponding to clinical practice. Furthermore, pharmacokinetic-pharmacodynamic parameters should be validated using standardized dosing, including a loading dose. Based on the pharmacokinetic data obtained, a population model for critically ill patients should be developed. Finally, the interference of colistin with extracorporeal methods should be quantified.
ER  -

RYCHLÍČKOVÁ, Jitka, Vendula KUBICKOVA, Pavel SUK a Karel URBANEK. Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review. \textit{Antibiotics-Basel}. BASEL: MDPI, 2023, roč.~12, č.~3, s.~1-17. ISSN~2079-6382. Dostupné z: https://dx.doi.org/10.3390/antibiotics12030437.

Podrobný výpis o publikaci